Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring.
NIR-II bioimaging
nanotechnology
rare earths
shortwave infrared imaging
theranostic
tumor therapy monitoring
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
06
2020
accepted:
14
09
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Therapeutic drug monitoring (TDM) in cancer, while imperative, has been challenging due to inter-patient variability in drug pharmacokinetics. Additionally, most pharmacokinetic monitoring is done by assessments of the drugs in plasma, which is not an accurate gauge for drug concentrations in target tumor tissue. There exists a critical need for therapy monitoring tools that can provide real-time feedback on drug efficacy at target site to enable alteration in treatment regimens early during cancer therapy. Here, we report on theranostic optical imaging probes based on shortwave infrared (SWIR)-emitting rare earth-doped nanoparticles encapsulated with human serum albumin (abbreviated as ReANCs) that have demonstrated superior surveillance capability for detecting micro-lesions at depths of 1 cm in a mouse model of breast cancer metastasis. Most notably, ReANCs previously deployed for detection of multi-organ metastases resolved bone lesions earlier than contrast-enhanced magnetic resonance imaging (MRI). We engineered tumor-targeted ReANCs carrying a therapeutic payload as a potential theranostic for evaluating drug efficacy at the tumor site.
Identifiants
pubmed: 33134314
doi: 10.3389/fmolb.2020.569415
pmc: PMC7575924
doi:
Types de publication
Journal Article
Langues
eng
Pagination
569415Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB018378
Pays : United States
Informations de copyright
Copyright © 2020 Shah, Gonda, Pemmaraju, Subash, Bobadilla Mendez, Berger, Zhao, He, Riman, Tan, Pierce, Moghe and Ganapathy.
Références
Cancer Biother Radiopharm. 2019 Apr;34(3):135-140
pubmed: 30973278
Mol Cancer. 2010 May 26;9:122
pubmed: 20504320
J Drug Deliv. 2012;2012:686108
pubmed: 22187654
Nat Biomed Eng. 2017;1:993-1003
pubmed: 29531851
Nano Res. 2019 Feb;12:273-279
pubmed: 31832124
Drug Deliv. 2018 Nov;25(1):564-575
pubmed: 29457518
Clin Cancer Res. 2020 May 15;26(10):2284-2289
pubmed: 32001481
Br J Radiol. 2018 Nov;91(1091):20170893
pubmed: 29565650
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Lancet. 1998 May;351 Suppl 2:SII9-16
pubmed: 9606361
J Nanomed Nanotechnol. 2018;9(5):
pubmed: 30613436
Onco Targets Ther. 2019 Mar 18;12:2047-2062
pubmed: 30936721
Chem Commun (Camb). 2017 Oct 10;53(81):11114-11117
pubmed: 28929142
J Oncol Pharm Pract. 2007 Dec;13(4):207-21
pubmed: 18045780
Pharmaceuticals (Basel). 2019 Jul 29;12(3):
pubmed: 31362406
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2104-13
pubmed: 27036008
Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150
pubmed: 29910657
Chemistry. 2015 Aug 3;21(32):11325-9
pubmed: 26177931
Bioinformatics. 2011 Jul 1;27(13):1806-13
pubmed: 21593135
Adv Mater. 2018 Mar;30(13):e1704934
pubmed: 29430735
ACS Omega. 2019 Dec 09;4(26):22214-22227
pubmed: 31891105
SLAS Technol. 2018 Jun;23(3):281-293
pubmed: 29115174
Chem Pharm Bull (Tokyo). 2018;66(4):382-390
pubmed: 29607904
Eur J Pharm Sci. 2014 Oct 1;62:243-50
pubmed: 24931189
Expert Rev Anticancer Ther. 2020 Mar;20(3):151-158
pubmed: 32067545
J Nucl Med. 2017 Jan;58(1):75-80
pubmed: 27493272
Chem Soc Rev. 2016 Mar 7;45(5):1432-56
pubmed: 26771036
Chem Eng Sci. 2015 Mar 24;125:75-84
pubmed: 25684779
Bioanalysis. 2009 Jun;1(3):507-11
pubmed: 21083145
Int J Pharm. 2007 Aug 16;341(1-2):207-14
pubmed: 17478065
Theranostics. 2017 Aug 23;7(15):3667-3689
pubmed: 29109768
Small. 2015 Dec 16;11(47):6347-57
pubmed: 26514367
Int J Pharm. 2012 Mar 15;424(1-2):107-14
pubmed: 22226875
J Biomed Opt. 2018 Mar;23(3):1-4
pubmed: 29564865
Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28
pubmed: 24579667
Diabetol Metab Syndr. 2011 Jun 15;3(1):11
pubmed: 21676260
Expert Opin Investig Drugs. 2019 Jan;28(1):1-5
pubmed: 30474425
Small. 2010 Aug 2;6(15):1631-40
pubmed: 20586056
Int J Pharm. 2010 Jun 30;393(1-2):176-84
pubmed: 20381598
Biomacromolecules. 2017 Dec 11;18(12):3869-3880
pubmed: 29032674
Beilstein J Nanotechnol. 2019 Aug 14;10:1707-1715
pubmed: 31501742
J Control Release. 2001 Jun 15;73(2-3):255-67
pubmed: 11516503
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Mater Chem B. 2020 May 6;8(17):3939-3948
pubmed: 32236239
Bioeng Transl Med. 2019 Sep 05;4(3):e10143
pubmed: 31572799
Front Bioeng Biotechnol. 2020 Jan 30;7:487
pubmed: 32083067
Curr Pharm Des. 2015;21(14):1800-16
pubmed: 25738490
Adv Healthc Mater. 2013 Sep;2(9):1236-45
pubmed: 23495216
Contrast Media Mol Imaging. 2019 Sep 22;2019:8946729
pubmed: 31598114
Theranostics. 2019 Sep 19;9(22):6719-6733
pubmed: 31588246
Nat Commun. 2013;4:2199
pubmed: 23873342
J Pharm Biomed Anal. 2004 Sep 3;35(5):1093-100
pubmed: 15336356
Adv Mater. 2016 Dec;28(47):10557-10566
pubmed: 27111654
Clin Pharmacol Ther. 2019 Jul;106(1):148-163
pubmed: 30107040